The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern …

This is a comment on" COVID-19, cytokines and immunosuppression: what can we learn
from severe acute respiratory syndrome?" Clin Exp Rheumatol. 2020 Mar-Apr; 38 (2): 337 …

Objective To analyze clinical characteristics and outcome of COVID-19 patients with
underlying rheumatic diseases (RD) on immunosuppressive agents. Method A case series …

The outbreak of coronavirus in the world has led to an uncertainty about treatment of
patients with autoimmune disorders because of their weakened immune system coupled …

Individuals with inflammatory rheumatic disease require special consideration with regard to
coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome …

There is concern that people with rheumatic disease, often treated with immunosuppressive
or immunomodulatory medication, may be at an increased risk of poor outcomes of novel …

The COVID-19 pandemic has already caused over 400 000 infections and led to over 17
000 deaths worldwide, dramatically disrupted daily life, and is placing extreme demands on …

The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

Current pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite drastic containment measures …

Purpose of review The COVID-19 outbreak has resulted in uncertainty for patients with
autoimmune rheumatic diseases for several reasons. They are concerned about their risk of …